Status:

RECRUITING

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Nervous System Disease

Immune System Disease

Eligibility:

All Genders

2-120 years

Brief Summary

Background: Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological...

Detailed Description

Study Description: In this study, we will characterize clinical neurologic presentations of patients with known or unevaluated primary and acquired errors of immunity. Investigating the underlying me...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Aged \>=2 years. To be seen at the NIH CC, participants must be \>=3 years of age.
  • Willing to allow specimens and data to be stored for future research.
  • Willing to allow genetic testing on their biospecimens.
  • Able to provide informed consent (for ages \>=18 years) or has parent(s) or guardian(s) who can provide permission to participate on their behalf (for ages \<18 years).
  • Decisionally impaired affected adult participants may have a legally authorized representative (LAR) to provide informed consent on their behalf.
  • Additional Inclusion Criterion for Affected Participants:
  • Has a primary or acquired immunodeficiency and known or suspected infection or inflammation of the nervous system or post-infection sequelae, based on clinical or imaging data provided by the referral facility, or is at risk of developing such a neurologic complication. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:
  • Any neurologic symptoms accompanied by CSF with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation, including immunoglobulin \[Ig\] G index or presence of oligoclonal bands).
  • Systemic infection or inflammatory disease with neurologic involvement.
  • Neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI).
  • Clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation.
  • History of infection or inflammatory process of the nervous system.
  • Affected participants must also have their own primary health care provider to manage their condition outside the NIH.
  • Additional Inclusion Criteria for Biological Relatives and Healthy Volunteers:
  • Is either a biological relative of an affected participant or is unrelated.
  • Does not have a known diagnosis of neuroinfectious disease or neuroinflammation.
  • EXCLUSION CRITERIA:
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Pregnant (for biological relatives and healthy volunteers).
  • Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.

Exclusion

    Key Trial Info

    Start Date :

    January 12 2024

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 1 2043

    Estimated Enrollment :

    350 Patients enrolled

    Trial Details

    Trial ID

    NCT06169150

    Start Date

    January 12 2024

    End Date

    October 1 2043

    Last Update

    September 25 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892